


CONTENTS

PHARMACOLOGY



Pharmacology - Volume 1

No. of Pages: 573

ISBN: 978-1-84826-180-8 (eBook)

ISBN: 978-1-84826-630-8 (Print Volume)

Pharmacology - Volume 2

No. of Pages: 392

ISBN: 978-1-84826-254-6 (eBook)

ISBN: 978-1-84826-704-6 (Print Volume)

For more information on e-book(s) and Print Volume(s) order, please [click here](#)

[Or contact : eolessunesco@gmail.com](mailto:eolessunesco@gmail.com)

CONTENTS**VOLUME I****An Introduction to Pharmacology 1**H. Majewski, *School of Medical Sciences, RMIT University, Australia*

1. History of Pharmacology
2. Pharmacodynamics and Receptors
3. Molecular Pharmacology
 - 3.1. Receptors: Ligand Gated Ion Channels
 - 3.2. Receptors: G-protein Coupled Receptors
 - 3.3. Enzyme Linked Membrane Receptors
 - 3.4. Nuclear Receptor Family
 - 3.5. Ion Channels
 - 3.6. Molecular Basis of Bacterial Chemotherapy
 - 3.7. Molecular Basis of Viral Chemotherapy
 - 3.8. Molecular Basis of Cancer Chemotherapy
4. Pharmacokinetics
5. Pharmacogenomics
6. Safety Pharmacology
7. Drug Discovery
8. Clinical Pharmacology
9. Pharmacology of the Nervous System
 - 9.1. Autonomic Pharmacology
 - 9.2. Neuropharmacology: Brain Neurotransmission
 - 9.3. Neuropsychopharmacology
 - 9.4. Pain and Analgesia
 - 9.5. Drugs used in Anesthesia
10. Muscle Relaxants
11. Gastrointestinal Pharmacology
12. Poisons, Venoms and Toxins
13. Reproductive Pharmacology
14. Drug Therapy of Inflammation
 - 14.1. Non Steroidal Anti-inflammatory Drugs
 - 14.2. Cromones
 - 14.3. Glucocorticoids
 - 14.4. Mediator Receptor Antagonists
 - 14.5. Disease Modifying Anti-rheumatoid Drugs
15. Immunopharmacology
16. Endocrine Pharmacology
17. Cardiovascular Pharmacology
 - 17.1. Heart Failure
 - 17.2. Angina
 - 17.3. Hypertension
 - 17.4. Disturbances to Cardiac Rhythm
 - 17.5. Disease Modifying Drug Strategies in Cardiovascular Disease
18. Pulmonary Pharmacology
 - 18.1. Allergies and Anaphylactic Shock

Neuropharmacology 42Emilio Badoer, *School of Medical Sciences, RMIT University, Melbourne, Victoria, Australia*

1. Introduction
2. Excitatory Amino Acids
 - 2.1. Receptors for Glutamate

- 2.1.1. NMDA Receptors
 - 2.1.1.1. Physiological Effects Of NMDA Receptors
 - 2.1.1.2. Role Of NMDA Receptors In Disease
 - 2.1.1.3. Agonists of NMDA Receptors
 - 2.1.1.4. Antagonists of NMDA Receptors
- 2.1.2. AMPA Receptors
 - 2.1.2.1. Physiological Effects of AMPA Receptors
 - 2.1.2.2. Role Of AMPA Receptors In Disease
 - 2.1.2.3. Agonists of AMPA Receptors
 - 2.1.2.4. Antagonists of AMPA Receptors
- 2.1.3. Kainate Receptors
 - 2.1.3.1. Physiological Effects of Kainate Receptors
 - 2.1.3.2. Role of Kainate Receptors in Disease
 - 2.1.3.3. Agonists Of Kainate Receptors
 - 2.1.3.4. Antagonists Of Kainate Receptors
- 2.1.4. Metabotropic Glutamate Receptors
 - 2.1.4.1. Physiological Effects of mGluRs
 - 2.1.4.2. Role of mGluRs in Disease
 - 2.1.4.3. Agonists of mGluRs
 - 2.1.4.4. Antagonists of mGluRs
- 3. Gamma-aminobutyric Acid (GABA)
 - 3.1. Receptors for GABA
 - 3.1.1. Ligand-gated Ion Channel GABA Receptors
 - 3.1.1.1. GABA_A Receptors
 - 3.1.1.2. Physiological effects of GABA_A receptors
 - 3.1.1.3. Role of GABA_A Receptors in Disease
 - 3.1.1.4. Agonists of GABA_A receptors
 - 3.1.1.5. Antagonists of GABA_A Receptors
 - 3.1.2. GABA_C Receptors
 - 3.1.2.1. Physiological Effects of GABA_C Receptors
 - 3.1.2.2. Role of GABA_C Receptors In Disease Receptors
 - 3.1.2.3. Agonists of GABA_C Receptors
 - 3.1.2.4. Antagonists of GABA_C Receptors
 - 3.1.3. G-Protein coupled GABA Receptors
 - 3.1.3.1. GABA_B Receptors
 - 3.1.3.1.1. Physiological effects of GABA_B Receptors
 - 3.1.3.1.2. Role of GABA_B Receptors In Disease
 - 3.1.3.1.3. Agonists of GABA_B Receptors
 - 3.1.3.1.4. Antagonists of GABA_B Receptors
- 4. Conclusion

Cardiovascular and Renal Pharmacology

66

Sheila A Doggrell and Julianne J. Reid, *College of Science, Engineering and Health, RMIT University, Melbourne, VIC 3001, Australia*

- 1. Diuretics
 - 1.1. Introduction
 - 1.2. Endogenous Diuretics
 - 1.3 Diuretics
 - 1.3.1. Nephron Structure
 - 1.3.2. Osmotic Diuretics
 - 1.3.3. Carbonic Anhydrase Inhibitors
 - 1.3.4. Loop Diuretics
 - 1.3.5. Thiazide and Thiazide-like Diuretics
 - 1.3.6. K⁺-Sparing Diuretics
- 2. Antiplatelet, Anticoagulants and Fibrinolytic Agents
 - 2.1. Introduction
 - 2.2. Brief Overview of Thrombus Formation

- 2.3. Antiplatelet Drugs
 - 2.3.1. Aspirin
 - 2.3.2. Purinergic P2Y₁₂ Receptor Antagonists
 - 2.3.3. GPIIb/IIIa Antagonists
- 2.4. Anticoagulants Drugs
 - 2.4.1. Heparin and Heparin Fragments
 - 2.4.2. Warfarin
 - 2.4.3. Fondaparinux
- 2.5. Fibrinolytic Agents
- 3. Drugs That Increase Blood Pressure
- 4. Drugs That Decrease Blood Pressure
 - 4.1. Systemic Hypertension
 - 4.1.1. Introduction
 - 4.1.2. Epidemiology
 - 4.1.3. Types of Systemic Hypertension
 - 4.2. Treatment of Systemic Hypertension
 - 4.2.1. Diuretics
 - 4.2.2. β -Adrenoceptor Antagonists (β -Blockers)
 - 4.2.3. Calcium Channel Blockers
 - 4.2.4. Inhibitors of the Renin-Angiotensin System
 - 4.2.5. α_1 -Adrenoceptor Antagonists
 - 4.2.6. α_2 -Adrenoceptor Agonists
 - 4.2.7. K_{ATP} Channel Openers
 - 4.2.8. Nitrovasodilators
 - 4.2.9. Aldosterone Receptor Antagonist
 - 4.3. Pulmonary Hypertension
- 5. Anti-Anginal Agents
 - 5.1. Introduction
 - 5.2. Types of Angina
 - 5.3. Approaches to the Treatment of Angina
 - 5.4. Treating Attacks of Angina
 - 5.5. Preventing Attacks of Angina
 - 5.6. Treatment of Variant Angina
- 6. Drugs Used in the Treatment of Heart Failure
 - 6.1. Introduction
 - 6.2. The Heart Failure Epidemic
 - 6.3. What is Heart Failure?
 - 6.4. Compensatory Changes in Heart Failure
 - 6.5. Drugs Used in the Treatment of Heart Failure
 - 6.5.1. Diuretics
 - 6.5.2. Cardiac Glycosides
 - 6.5.3. Vasodilation and ACE Inhibitors
 - 6.5.4. β -Adrenoceptor Agonists/Antagonists
 - 6.5.5. Aldosterone Receptor Antagonist
 - 6.5.6. AT₁-Receptor Antagonists
 - 6.5.7. Amiodarone
 - 6.5.8. Nesiritide (BNP)
 - 6.5.9. Levosimendan
- 7. Cardiac Arrhythmias and Anti-Arrhythmic Drugs
 - 7.1. Introduction
 - 7.2. Mechanism of Arrhythmias
 - 7.3. Cardiac Action Potential
 - 7.4. The Original Classification
 - 7.5. Class I: Na⁺ Channel Blockade
 - 7.6. Class II β -Adrenoceptor Antagonists
 - 7.7. Class I and II: Propranolol
 - 7.8. Class III Prolongation of the Action Potential: K⁺ Channel Blockers
 - 7.9. Class I and III: Na⁺ and K⁺ Channel Blockers

- 7.10. Class II and III: (±)-Sotalol
- 7.11. Class IV: Ca²⁺ Channel Blockers
- 7.12. Class I-IV Amiodarone
- 7.13. Class V: Bradycardiac Agents
- 7.14. Digoxin
- 8. Drugs Used in the Treatment of Dyslipidemia
 - 8.1. Introduction
 - 8.2. Physiological and Pathophysiological Role of Cholesterol
 - 8.3. Causes of Hyperlipidemia
 - 8.4. Drugs Used to Treat Hyperlipidemia
 - 8.4.1. Statins
 - 8.4.2. Fibric Acid Derivatives (Fibrates)
 - 8.4.3. Bile Acid-Binding Resins
 - 8.4.4. Nicotinic Acid
 - 8.4.5. Ezetimibe
 - 8.4.6. Orlistat
- 9. Drugs Used In the Treatment of Kidney Failure

Clinical Pharmacology **119**
 Winston Spencer Liauw, *Cancer Care Centre, St George Hospital, Gray Street, Kogarah NSW 2217, Australia*

- 1. Introduction
- 2. Clinical Pharmacokinetics
 - 2.1. Clearance
 - 2.2. Volume of Distribution
 - 2.3. Half-life
 - 2.4. Dose Determination
 - 2.5. ADME: Drug Absorption and Bioavailability
 - 2.6. ADME: Drug Distribution
 - 2.7. ADME: Drug Metabolism
 - 2.8. ADME: Elimination
 - 2.9. Drug Dosing in Pediatric and Geriatric Populations
- 3. Pharmacodynamics
- 4. Pharmacogenetics
- 5. Quality Use of Medicines
- 6. Therapeutic Drug Monitoring
- 7. Population Pharmacokinetics
- 8. Toxicology
- 9. Clinical Pharmacology and Drug Development
- 10. Conclusion

Pharmacokinetics: How Does The Body Handle Drugs? **148**
 Olavi Pelkonen, *Department of Pharmacology and Toxicology, University of Oulu, Finland*
 Jorma Ahokas, *School of Medical Sciences, RMIT-University, Bundoora, Victoria, Australia*

- 1. Introduction
- 2. Movement of Drugs in the Body
 - 2.1. Mass transport
 - 2.2. Passage through biological membranes
- 3. Absorption of Drugs
 - 3.1. Oral Administrations
 - 3.2. Parenteral route of entry
 - 3.2.1. Percutaneous
 - 3.2.2. Nose and eyes
 - 3.3. Inhalation

- 3.4. Bioavailability
 - 3.4.1. Physiological Factors
 - 3.4.2. Other Properties
- 3.5. Therapeutic delivery systems (prodrugs, implants etc)
4. Distribution
 - 4.1. Blood brain barrier (BBB)
 - 4.2. Placental distribution
5. Elimination of Drugs
 - 5.1. Metabolism
 - 5.1.1. Phase I Enzymes
 - 5.1.2. Phase II Enzymes
 - 5.1.3. Tissue distribution of drug metabolising enzymes
 - 5.1.4. Enzyme Inhibition
 - 5.1.5. Enzyme Induction
 - 5.1.6. Genetic and other factors
 - 5.2. Excretion
 - 5.2.1. Factors affecting urinary excretion of drugs
 - 5.2.2. Other routes of drug excretion
6. Mathematical parameters in pharmacokinetics
 - 6.1. Volume of distribution
 - 6.2. Elimination kinetics
 - 6.3. Half-life
 - 6.4. Clearance
 - 6.5. Two Compartment Model
 - 6.6. Saturation Model
7. Studying pharmacokinetics during drug development
8. Conclusions

Pharmacogenomics And Pharmacogenetics

173

Andrew A Somogyi and Janet K Coller, *Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia*

1. Introduction
2. How Do We Determine a Person's Phenotype?
3. How Do We Determine a Person's Genotype?
4. Nomenclature Used For Genetic Variants
5. History of Pharmacogenetics and Genomics
6. Pharmacogenetics of Drug Metabolising Enzymes and Transporters: Pharmacokinetics
 - 6.1. Drug Metabolizing Enzymes
 - 6.1.1. Genetic Basis of the Polymorphisms
 - 6.1.2. Impact of Pharmacogenetics on Drug Metabolism and Pharmacokinetics
 - 6.2. Drug Transporters
 - 6.2.1. Genetic Basis of the Polymorphisms
 - 6.2.2. Impact of Pharmacogenetics on Drug Distribution Pharmacokinetics
7. Pharmacogenetics of Drug Targets: Pharmacodynamics
 - 7.1. G-Protein Coupled Receptors
 - 7.1.1. Beta Adrenoceptors
 - 7.1.2. Beta 1 Adrenoceptors
 - 7.2. Enzymes as Drug Targets
 - 7.3. Ion Channel Drug Targets
 - 7.4. Transporters as Drug Targets
8. Pharmacogenetics and Drug Safety
 - 8.1. TMPT and Thiopurine Dosing
 - 8.2. UGT1A1 Polymorphism and Irinotecan Toxicity
9. Future Directions

Neuropsychopharmacology**194**

Mirjam A.F.M. Gerrits and Jan M. van Ree, *Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands*

1. Introduction
2. Chemical synaptic transmission in the central nervous system
3. Psychopharmacology and psychotropic drugs
4. Antipsychotics
 - 4.1. Schizophrenia
 - 4.2. Schizophrenia
 - 4.3. Antipsychotic Drugs
 - 4.3.1. Mechanism of Action
 - 4.3.2. Side Effects of Antipsychotics
 - 4.3.3. Novel Targets for Antipsychotic Drug Action
5. Antidepressants and mood stabilizers
 - 5.1. Etiology and Pathogenesis of Affective Disorders
 - 5.2. Antidepressive Drugs and Mood-stabilizers
 - 5.2.1. Monoamine Oxidase Inhibitors
 - 5.2.2. Tricyclic Antidepressants
 - 5.2.3. Selective 5-HT Uptake Inhibitors
 - 5.2.4. Newer, 'Atypical' Antidepressant Drugs
 - 5.2.5. Mood-stabilizers
6. Anxiolytics
 - 6.1. Benzodiazepines
 - 6.1.1. Mechanism of Action
 - 6.1.2. Therapeutic and Side Effects
 - 6.1.3. Pharmacokinetic Aspects

Endocrine Pharmacology**222**

Chen Chen, *School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia*

1. Introduction
 - 1.1. Concept of Hormone Action:
 - 1.1.1. Hormone Synthesis and Secretion:
 - 1.1.2. Feedback Regulation:
 - 1.1.3. Paracrine and Autocrine Regulation:
 - 1.1.4. Hormone Rhythms and Pulsatility:
 - 1.2. Endocrine Organs:
 - 1.3. Control of Hormone Secretion:
 - 1.3.1. Morphology of Endocrine Cells:
 - 1.3.2. Composition of Mature Secretory Granules:
 - 1.3.3. Regulation of Exocytosis By Calcium:
 - 1.3.4. Modulation of Exocytosis By Protein Kinase C:
2. Neuroendocrinology and Pituitary Diseases
 - 2.1. Pharmacologic Principles
 - 2.2. Diseases of the Pituitary
 - 2.2.1. Pituitary Hypofunction (Hypopituitarism)
 - 2.2.2. Pituitary Hyperfunction
 - 2.2.3. Growth Hormone Excess (Acromegaly)
 - 2.2.4. GH Deficiency
3. Thyroid Diseases and Disorders of Metabolic Rate
 - 3.1. Hypothyroidism
 - 3.2. Hyperthyroidism
4. Disorders of Carbohydrate Metabolism
 - 4.1. Insulin Receptor and Function
 - 4.2. Counter-Regulatory Hormones to Insulin

- 4.3. Diabetes Mellitus
- 4.4. Insulin in the Treatment of Diabetes Mellitus
- 4.5. Oral Hypoglycemic Drugs for Diabetes
- 4.6. Hypoglycemia

Overview on Gastrointestinal Pharmacology

241

Stefano Evangelista, *Menarini Ricerche spa, Firenze, Italy*

1. Introduction
2. Drugs that Control Gastric Acid Secretion and Treat Peptic Ulcers
 - 2.1. Antacids
 - 2.2. Histamine (H₂) Receptor Antagonists
 - 2.3. Proton Pump Inhibitors (PPIs)
 - 2.4. *Helicobacter pylori* (H. pylori) Therapy
3. Drugs Stimulating Gastrointestinal Motility
 - 3.1. Dopamine D₂-receptor Antagonists
 - 3.2. Serotonin 5-HT₄ Receptor Agonists
 - 3.3. Macrolides
4. Drugs to Treat Constipation
 - 4.1. Laxatives
5. Drugs to Treat Diarrhea
 - 5.1. Antidiarrheal Agents
6. Drugs to Treat Emesis
 - 6.1. Antiemetic Agents
7. Drugs to Treat Irritable Bowel Syndrome (IBS)
 - 7.1. Spasmolytics
 - 7.2. Serotonin Compounds: 5-HT₃ Receptor Antagonist and 5-HT₄ Receptor Agonists
8. Drugs to Treat Inflammatory Bowel Disease (IBD)
 - 8.1. Anti-IBD Therapies

Poisons, Venoms and Toxins

262

Koh Dawn Chin Ing, *Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

Tok Pei Loo, *Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

Chai Siaw Ching, *Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

Arunmozhiarasi Arumugam, *Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

Kandiah Jeyaseelan, *Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

Dannandan Jeyaseelan, *Box Hill Hospital, Nelson Road, Box Hill, Victoria 3128, Australia.*

1. Introduction
2. Categories of Poison
 - 2.1. Physical Agents
 - 2.2. Chemical Agents
 - 2.2.1. Metals as Poisons
 - 2.2.2. Alcohols - Delicious Poisons
 - 2.2.3. Glycosides and Cyanogenic Compounds-Plant Poisons
 - 2.2.4. Insecticides and Herbicides-Useful Poisons
 - 2.2.5. Over the Counter Analgesics
 - 2.2.6. Central Nervous System (CNS) Depressants
 - 2.2.7. Drugs of Abuse
 - 2.3. Biological Agents
 - 2.3.1. Plant and Microbial Toxins
 - 2.3.2. Animal Venoms and Toxins

- 2.3.2.1. Amphibian Toxins
- 2.3.2.2. Marine Toxins
- 2.3.2.3. Reptile Toxins
- 2.3.2.4. Arthropod Toxins
- 3. Toxins in Therapy
 - 3.1. Animal Toxins in Therapy
 - 3.2. Plant Toxins in Therapy
- 4. Concluding Remarks

Safety Pharmacology Assessment and Associated Regulations **285**

Jega Iswaran, *Biota Holdings Ltd, 10/585 Blackburn Road, Notting Hill, Vic 3168, Australia*
 Jorma Ahokas, *School of Medical Sciences, RMIT-University, Bundoora, Victoria 3083, Australia*

- 1. Introduction
- 2. Drug Screening Studies for Assessing Pharmacological Activity
- 3. Safety Pharmacology Studies in the Context of Regulatory Guidelines
- 4. Use of *in vitro* Systems and *in vivo* Models for Safety Pharmacology Testing
 - 4.1. Core Battery Studies
 - 4.1.1. Cardiovascular System
 - 4.1.2. Respiratory System
 - 4.1.3. Central Nervous System
 - 4.2. Supplemental Studies
 - 4.2.1. Renal/Urinary System
 - 4.2.2. Gastro-intestinal System
 - 4.2.3. Autonomic Nervous System
 - 4.2.4. Immune System
 - 4.2.5. Dependency Potential
 - 4.2.6. Effects on Skeletal Muscle
 - 4.2.7. Endocrine System
- 5. Concluding Remarks

Pharmacodynamics in Pharmacology **319**

Terry P. Kenakin, *GlaxoSmithKline Research and Development, USA*

- 1. Introduction
- 2. Pharmacological Receptors
- 3. What is Pharmacodynamics?
- 4. Definitions of Pharmacological Terms
- 5. Affinities
 - 5.1. Micro- and Macro-Affinity
- 6. Efficacy
- 7. The Operational Model for Agonism
- 8. Drug Antagonism
 - 8.1. Orthosteric Antagonism
 - 8.2. Allosteric Modulation
- 9. Partial Agonism
- 10. Inverse Agonism
- 11. Data-Driven Pharmacodynamics in Drug Discovery
 - 11.1. Agonists
 - 11.2. Antagonists
- 12. Conclusions

Index **355**

About EOLSS **361**

VOLUME II

The Autonomic Nervous System**1**James Ziogas and Fred Mitchelson, *Department of Pharmacology, University of Melbourne, Parkville Victoria, 3010, Australia.*

1. Introduction
2. Anatomical and Functional Organization of the Efferent Peripheral Nervous Systems
 - 2.1. Somatic and Autonomic Nerves
3. Sympathetic and Parasympathetic Divisions of the Autonomic Nervous System
 - 3.1. Anatomical considerations
 - 3.2. Physiological considerations
 - 3.3. Pharmacological and Biochemical considerations
4. Noradrenergic transmission
 - 4.1. Synthesis
 - 4.2. Storage
 - 4.3. Release
 - 4.4. Inactivation
 - 4.4.1. Neuronal Uptake
 - 4.4.2. Extra-neuronal Uptake
 - 4.4.3. Metabolism
 - 4.5. Receptors for Noradrenaline
 - 4.5.1. Adrenoceptor Structure and Signaling
 - 4.5.2. Targeting α -adrenoceptors
 - 4.5.3. Targeting β -adrenoceptors
5. Cholinergic Transmission
 - 5.1. Synthesis
 - 5.2. Storage
 - 5.3. Release
 - 5.4. Inactivation
 - 5.4.1. Cholinesterase inhibitors
 - 5.4.2. Targeting Acetylcholinesterase
 - 5.5. Receptors for Acetylcholine
 - 5.5.1. Nicotinic Cholinoceptors
 - 5.5.2. Muscarinic Cholinoceptors
 - 5.5.3. Targeting Nicotinic Cholinoceptors
 - 5.5.4. Targeting Muscarinic Cholinoceptors
 - 5.5.4.1 Agonists
 - 5.5.4.2 Naturally occurring muscarinic agonists
 - 5.5.4.3 Synthetic muscarinic agonists
 - 5.5.4.4 Muscarinic cholinergic antagonists
 - 5.5.4.5 Allosteric modulators and allosteric agonists
6. Conclusion

Drugs on Skeletal Muscle**31**Michael W. Nott, *RMIT University, Discipline of Pharmaceutical Sciences, Bundoora West campus, Bundoora, Victoria, Australia*

1. Introduction
2. Neuromuscular Transmission and Contraction in Skeletal Muscle
 - 2.1. Safety Factor in Transmission
 - 2.2. Train of Four and Tetanic Stimulation
 - 2.3. Twitch, Tetanic Contraction and Tremor
3. Neuromuscular Blocking Drugs
4. Non-depolarizing Neuromuscular Blocking Drugs
 - 4.1. Mechanism of Action

- 4.2. Tubocurarine
- 4.3. Gallamine, Benzoquinonium and Alcuronium
- 4.4. Aminosteroid Compounds
 - 4.4.1. Pancuronium
 - 4.4.2. Vecuronium
 - 4.4.3. Rocuronium
- 4.5. Bisbenzyl-isoquinolinium Compounds
 - 4.5.1. Atracurium and Cisatracurium
 - 4.5.2. Mivacurium
- 4.6. Reversal of Non-depolarizing Neuromuscular Block by Anticholinesterases
- 4.7. Other Neuromuscular Uses of Anticholinesterases
- 4.8. Pharmacokinetics of Non-depolarizing Neuromuscular Blocking Drugs
 - 4.8.1. Clearance of Non-depolarizing Neuromuscular Blocking Drugs and Duration of Action
5. Depolarizing Neuromuscular Blocking Drugs
 - 5.1. Mechanism of Action
 - 5.2. Succinylcholine
 - 5.2.1. Prolonged Block due to Reduced Butyrylcholinesterase Activity
 - 5.2.2. Malignant Hyperthermia
 - 5.2.3. Other adverse effects of succinylcholine
6. Other Drugs that Impair Neuromuscular Transmission
 - 6.1. Antibacterial Drugs
 - 6.2. Quinine and Other Quinoline Derivatives
 - 6.3. Hemicholinium
 - 6.4. Vesamicol
 - 6.5. Botulinum toxin
7. Drugs that Directly Affect Muscle Contractility
 - 7.1. Caffeine
 - 7.2. β_2 -Adrenoceptor Agonists
 - 7.2. Anabolic Steroids and Peptides
 - 7.3. Dantrolene and Azumolene
 - 7.4. Statins
8. Conclusion

The Pharmacotherapy Of Inflammation

59

Alastair G. Stewart, *Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia.*

Graham A. Mackay, *Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia.*

1. Introduction
2. The major mediators of inflammation and their origins
 - 2.1. Histamine and other vasoactive amines
 - 2.2. Kinins
 - 2.3. Complement
 - 2.4. Clotting factor cascade – thrombin and activated protein C (APC)
 - 2.5. Arachidonic acid (AA) metabolites and platelet activating factor
 - 2.5.1. Cyclo-oxygenases
 - 2.5.2. Production and degradation of prostanoids
 - 2.5.3. Prostaglandin E₂ (PGE₂)
 - 2.5.4. Prostaglandin D₂ (PGD₂)
 - 2.5.5. Prostaglandin F_{2 α} PGF_{2 α}
 - 2.5.6. Prostacyclin (PGI₂)
 - 2.5.7. Thromboxane A₂
 - 2.5.8. Therapeutic exploitation of prostanoids and their receptors
 - 2.5.9. 5-lipoxygenase (5LO)
 - 2.5.10. Cysteinyl Leukotrienes (Cys-LTs)
 - 2.5.11. Leukotriene B₄ (LTB₄)

- 2.5.12. Platelet-activating factor (PAF)
- 2.6. Free radicals
 - 2.6.1. Nitric oxide (NO)
 - 2.6.2. Reactive oxygen species
- 2.7. Cytokines and chemokines
- 2.8. Neuropeptides
- 2.9. Redundancy and synergy between inflammatory mediators
- 2.10. Endogenous down-regulators of inflammation
 - 2.10.1. Annexin
 - 2.10.2. Lipoxins, Resolvins and Protectins
- 2.11. Temporal aspects of bioactive lipid formation
- 3. Anti-inflammatory drugs
 - 3.1. Non-steroidal anti-inflammatory drugs (NSAIDs)
 - 3.1.1. Traditional NSAIDs
 - 3.1.1.1. Aspirin
 - 3.1.1.2. Paracetamol
 - 3.1.2. COX-2 selective NSAIDs
 - 3.2. Cromones (or chromones)
 - 3.3. Glucocorticoids (GCS)
 - 3.3.1. Mechanism of action.
 - 3.3.2. Dose and indication limiting adverse effects of glucocorticoids
 - 3.4. Mediator receptor antagonists
 - 3.4.1. Histamine receptor blockers
 - 3.4.2. Leukotriene receptor antagonists
 - 3.4.3. IL-1 receptor antagonists
 - 3.4.4. Adhesion and co-stimulatory molecule blockers
 - 3.4.5. Emerging receptor targets
 - 3.5. Cytokine-neutralising agents
 - 3.5.1. Anti-TNF agents
 - 3.6. Disease modifying anti-rheumatoid drugs (DMARDs)
 - 3.6.1. Methotrexate
 - 3.6.2. Leflunomide
 - 3.6.3. Sulfasalazine
 - 3.6.4. Gold compounds
 - 3.6.5. Penicillamine
 - 3.6.6. Hydroxychloroquine and chloroquine
 - 3.6.7. Biological DMARDs
 - 3.6.8. Cyclosporine
 - 3.7. Immunosuppressant anti-inflammatory agents
 - 3.7.1. Glucocorticoids (GCS)
 - 3.7.2. Calcineurin inhibitors and related compounds
 - 3.7.2.1. Cyclosporine and Tacrolimus
 - 3.7.2.2. Sirolimus (rapamycin)
 - 3.7.3. Cytotoxic agents
 - 3.7.4. Antibody therapies
 - 3.7.4.1. Intravenous immunoglobulin (IVIG) therapy
 - 3.8. Miscellaneous anti-inflammatory agents
 - 3.8.1. Gout
 - 3.8.1.1. Colchicine
 - 3.8.1.2. Allopurinol
 - 3.8.2. N-acetyl cysteine
 - 3.8.3. Fish oil
- 4. The integrated treatment of inflammatory disorders: selected examples
 - 4.1. Asthma
 - 4.1.1. Short-acting β_2 Adrenoceptor Agonists (SABA)
 - 4.2. Sepsis
- 5. Conclusions

Reproductive Pharmacology**109**

Jocelyn N. Pennefather, *Department of Pharmaceutical Biology, Victorian College of Pharmacy, Monash University, Parkville, Vic 3052, Australia*

Claire Garrett, *Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Vic 3052, Australia*

Luba D. Tomaska, *Office of Chemical Safety, Department of Health and Ageing, Woden, ACT 2606, Australia*

Elizabeth H. Brown, *Department of Human Physiology and Anatomy, Faculty of Health Sciences, La Trobe University, Vic 3086, Australia*

1. Introduction
2. Reproductive Glands and Hormones and Their Regulation
 - 2.1. The Hypothalamic Factor
 - 2.2. The Pituitary Hormones
 - 2.3. The Gonadal Hormones
 - 2.3.1. Androgens
 - 2.3.2. The Female Sex Steroids
 - 2.3.3. Gonadal Peptides
 - 2.4. Prostanoids
 - 2.5. Steroid Hormone Receptors and Drugs Targeting Them
 - 2.5.1. The Androgen Receptor
 - 2.5.2. Estrogen Receptors
 - 2.5.3. Progesterone Receptors
3. Testicular Function and its Control
4. The Menstrual Cycle and Drugs used in Menstrual Disorders and the Menopause
 - 4.1. The Menstrual Cycle
 - 4.1.1. Ovarian Events
 - 4.1.2. Uterine Events
 - 4.1.3. Hormonal Control of the Menstrual Cycle
 - 4.1.4. The Menstrual Cycle During the Lifespan
 - 4.2. Menstrual Cycle Disorders and Their Treatment
 - 4.2.1. Amenorrhea
 - 4.2.2. Polycystic Ovarian Syndrome (PCOS)
 - 4.2.3. Menorrhagia
 - 4.2.4. Dysmenorrhea
 - 4.2.5. Endometriosis
 - 4.3. Management of the Menopause and Disorders Associated with the Menopause with Hormonal Products (HRT)
5. Fertility and Conception
 - 5.1. Hormonal Contraception
 - 5.1.1. The Combined Oral Contraceptive Pill
 - 5.1.2. Progestogen-only Methods of Contraception
 - 5.1.3. Hormonal Contraception for Men
 - 5.2. Drugs used in Erectile Dysfunction
 - 5.3. Management of Infertility
6. Pregnancy and Parturition, Lactation and Pharmacological Interventions
 - 6.1. Drug Treatments in Pregnancy
 - 6.2. Induction of Labor
 - 6.3. Pain Relief in Labor
 - 6.4. Management of Third Stage of Labor
 - 6.5. Drugs used in Premature Labor
 - 6.6. Drugs Modifying Lactation
7. Environmental and Other Non-therapeutic Agents Affecting Reproduction and Development
 - 7.1. Exposure to EDs
 - 7.2. Mechanism of Action
 - 7.3. Effects of EDs
 - 7.4. Do Xenoestrogens and Other EDs Pose a Risk to Human Health?
 - 7.5. Examples of Potential EDs

- 7.5.1. Phytoestrogens
 - 7.5.2. Phthalates
 - 7.5.3. Vinclozolin
8. Conclusion

Immunopharmacology: A guide to Novel Therapeutic Tools

160

Francesco Roselli, *Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy*
 Emilio Jirillo, *Department of Internal Medicine, Immunology and Infectious Disease, University of Bari, Italy.*
National Institute for Digestive Disease, Castellana Grotte, Bari, Italy

1. Introduction
2. B cell targeted immunotherapy: Rituximab
3. Lymphocyte trafficking inhibitors: Natalizumab and Efalizumab
 - 3.1. Natalizumab
 - 3.2. Efalizumab
4. Costimulatory molecules antagonists (Abatacept, Betalcept, Alefacept)
 - 4.1. Abatacept
 - 4.2. Betalcept
 - 4.3. Alefacept
5. Interleukin-2 receptor antagonists: Basiliximab, Daclizumab
 - 5.1. Basiliximab
 - 5.2. Daclizumab
6. Antagonists of soluble mediators of inflammation
 - 6.1 TNF- α antagonists: Infliximab, Etanercept, Adalimumab
 - 6.1.1. Infliximab
 - 6.1.2. Etanercept
 - 6.1.3. Adalimumab
 - 6.2. Interleukin-1 Receptor Antagonist (Anakinra)
 - 6.3. Interleukin-6 receptor antagonist (tocilizumab)
7. Antagonist of Immunoglobulin E (Omalizumab)
8. Interleukin therapy in oncology
 - 8.1. Interleukin-2
 - 8.2. Interleukin-2/diphtheria toxin conjugate (Ontak)
 - 8.3. Interferon- γ and Interleukin-12
9. Perspectives and future developments

Pain Pharmacology and Analgesia

193

Maree T. Smith, *Centre for Integrated Preclinical Drug Development and School of Pharmacy, The University of Queensland, St Lucia Campus, Brisbane, Queensland, Australia.*
 Samantha M. South, *Centre for Integrated Preclinical Drug Development and School of Pharmacy, The University of Queensland, St Lucia Campus, Brisbane, Queensland, Australia.*

1. Pain definitions
 - 1.1. Pain – According to Duration
 - 1.1.1. Acute Pain
 - 1.1.2. Chronic Pain
 - 1.2. Pain – According to Type
 - 1.2.1. Nociceptive pain
 - 1.2.2. Inflammatory pain
 - 1.2.3. Neuropathic pain
 - 1.3. Emotional Response to Pain
2. Pain signaling system
 - 2.1. Pain detection
 - 2.2. Functional Characteristics of the Pain Signaling Apparatus
 - 2.2.1. Nociceptors
 - 2.2.2. Primary Sensory Neurones

- 2.2.3. Primary Sensory Neurons and the Spinal Cord
- 2.2.4. Spinal Cord Neurons
 - 2.2.4.1. Projection Neurons and the Spinal Cord
 - 2.2.4.2. Spinal Interneurons
- 2.3. Pain characteristics
- 2.4. Animal Models of Nociception/Pain
- 2.5. Neurochemical Characteristics of the Nociceptive Signaling System
 - 2.5.1. Transmission of Nociceptive Information from the Periphery to the Spinal Cord
- 2.6. Nociceptive Neurotransmitters and their Target Receptors
 - 2.6.1. Excitatory Amino Acids and their Receptors
 - 2.6.1.1. Glutamate Receptors
 - 2.6.1.2. NMDA Receptors
 - 2.6.1.3. AMPA Receptors
 - 2.6.1.4. Kainate Receptors
 - 2.6.1.5. Metabotropic Glutamate Receptors (mGluRs)
 - 2.6.1.6. Excitatory Amino Acid Transporters (EEATs)
 - 2.6.1.7. Glycine Transporters (GlyTs)
 - 2.6.2. Co-containment of Neurotransmitters in Nerve Terminals
- 2.7. Descending Modulation of Nociception
- 3. Neural plasticity and pain
 - 3.1. Inflammation
 - 3.1.1. Inflammation and Peripheral Sensitization
 - 3.1.2. Inflammation and Post-translational Changes
 - 3.1.3. Inflammation-Induced Transcriptional Changes: Effects on Peripheral Sensitization
 - 3.1.4. Inflammation and Central Sensitization
 - 3.2. Peripheral Nerve Injury and Neuropathic Pain
 - 3.3. Central Sensitization and Neuropathic Pain
 - 3.3.1. Dysfunction of Central Inhibition
 - 3.4. Non-Neuronal Cells in the Dorsal Root Ganglia and the CNS
 - 3.4.1. Satellite Glia Cells in Dorsal Root Ganglia
 - 3.4.2. Activated Microglia and Astrocytes in the CNS
- 4. Endogenous pain relief system
 - 4.1. Processing of low-intensity stimuli
 - 4.2. Processing of high-intensity stimuli
 - 4.3. Opioids
 - 4.3.1. Heterodimeric Opioid Receptors
 - 4.4. Tolerance to Opioids
 - 4.4.1. Innate Tolerance
 - 4.4.2. Acquired Tolerance
 - 4.4.2.1. Pharmacodynamic Tolerance
 - 4.4.2.2. Pharmacokinetic Tolerance
 - 4.4.3. Tolerance to Opioid-Related Side-Effects
 - 4.4.4. Prevention of the Development of Analgesic Tolerance
- 5. Strategies for producing pain therapeutics
 - 5.1. Modulation of the NMDA Receptor-Nitric Oxide Synthase Cascade
 - 5.1.1. NMDA receptor antagonists
 - 5.1.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
 - 5.1.3. NOS inhibitors
 - 5.1.4. Substance P antagonists
 - 5.2. Inhibition of Pro-nociceptive Neurotransmitter Release
 - 5.2.1. N-type Calcium Channel Blockers
 - 5.2.2. Gabapentinoids
 - 5.2. Voltage-Gated Sodium Channels as Potential Drug Targets in Persistent Pain States
 - 5.2.1. Nav1.8
 - 5.2.2. Nav1.9
 - 5.2.3. Sodium Channels in Inflammatory Pain
 - 5.2.4. Sodium Channels in Neuropathic Pain
 - 5.3. Transient Receptor Potential Vanilloid Receptor-1 (TRPV1) as a Potential Drug Target

- 5.4. Purinergic Receptors
- 5.5. Nerve Growth Factor (NGF) and trkA Receptors
- 5.6. Brain-Derived Neurotrophic Factor (BDNF) and trkB Receptors
- 5.7. Nicotinic Cholinergic Agonists
- 5.8. Neuronal Nicotinic Cholinergic Antagonists
- 5.9. Anti-opioid Peptides
 - 5.9.1. CCK-8
 - 5.9.2. Dynorphin A
- 5.10. Adenosine
- 5.11. Cannabinoids
6. Pain assessment and pain assessment tools
7. Pharmacological treatment of pain: analgesics and adjuvants
 - 7.1. Treatment of Pain in the Clinical Setting
 - 7.2. Major Aims of the Treatment of Clinical Pain
 - 7.3. Pharmacological management of pain: current treatment guidelines
 - 7.4. Controlled or Sustained Release Oral Formulations
8. Analgesic Agents
 - 8.1. Non-opioid Analgesics
 - 8.1.1. Paracetamol
 - 8.1.2. Non-steroidal anti-inflammatory drugs, (NSAIDs)
 - 8.2. Opioid Analgesics
 - 8.3. Commonly Prescribed Opioid Analgesics
 - 8.3.1. Strong Opioid Analgesics
 - 8.3.1.1. Morphine
 - 8.3.1.2. Oxycodone
 - 8.3.1.3. Methadone
 - 8.3.1.4. Hydromorphone
 - 8.3.1.5. Fentanyl
 - 8.3.2. Weak Opioid Analgesics
 - 8.3.2.1. Codeine
 - 8.3.2.2. Pethidine (Meperidine)
 - 8.3.2.3. Tramadol
 - 8.3.3. Partial Opioid Agonists/Antagonists: Buprenorphine
 - 8.4. Opioid-Related Adverse effects
 - 8.5. Adjuvant analgesics
 - 8.5.1. Tricyclic Antidepressants
 - 8.5.2. Anticonvulsants
 - 8.5.3. Anti-arrhythmics
 - 8.6. Topical Agents
 - 8.6.1. Lignocaine (lidocaine)
 - 8.6.2. Capsaicin
 - 8.7. NMDA receptor antagonists
 - 8.7.1. Ketamine
 - 8.7.2. Dextromethorphan
 - 8.8. Alpha(2)-Adrenergic Receptor Agonists
 - 8.9. Invasive Procedures
 - 8.9.1. Neurolytic Celiac Plexus Blockade
 - 8.9.2. Implantable Intrathecal Drug Delivery
 - 8.9.3. Spinal Cord Stimulation
9. Conclusion

Anesthetics**269**

Amanda Baric, *Department of Anesthesia and Perioperative medicine, The Northern Hospital, Melbourne, Australia.*

David Pescod, *Department of Anesthesia and Perioperative medicine, The Northern Hospital, Melbourne, Australia.*

1. Inhalation Agents
 - 1.1. Introduction
 - 1.2. Pharmacokinetics and Pharmacodynamics
 - 1.3. Specific Agents
 - 1.3.1. Diethyl Ether (Ether)
 - 1.3.2. Chloroform
 - 1.3.3. Cyclopropane
 - 1.3.4. Trichloroethylene
 - 1.3.5. Halogenated Alkanes and Ethers
 - 1.3.6. Nitrous Oxide.
 - 1.3.7. Xenon
2. Neuromuscular Blocking Agents (Muscle Relaxants)
 - 2.1. Introduction
 - 2.2. Non-Depolarising Muscle Relaxants
 - 2.2.1. Tubocurarine (1935)
 - 2.2.2. Metocurine (dimethyl tubocurarine chloride/bromide)
 - 2.2.3. Alcuronium (1961)
 - 2.2.4. Gallamine (1948)
 - 2.2.5. Pancuronium (1968)
 - 2.2.6. Vecuronium (1983)
 - 2.2.7. Atracurium (1980s)
 - 2.2.8. Cis-atracurium (1995)
 - 2.2.9. Mivacurium (1993)
 - 2.2.10. Rocuronium (1994)
 - 2.2.11. Sugammadex (2003)
 - 2.2.12. Rapacuronium
 - 2.3. Reversal Drugs (Anticholinesterase)
 - 2.4. Depolarising Muscle Relaxants (Suxamethonium or Succinylcholine)
3. Local Anesthetics
 - 3.1. Introduction
 - 3.2. Pharmacokinetics and Pharmacodynamics
 - 3.3. Toxicity
 - 3.4. Specific Agents
 - 3.4.1. Cocaine
 - 3.4.2. Procaine
 - 3.4.3. Chlorprocaine
 - 3.4.4. Tetracaine (Amethocaine)
 - 3.4.5. Lidocaine
 - 3.4.6. Prilocaine
 - 3.4.7. Mepivacaine
 - 3.4.8. Bupivacaine
 - 3.4.9. Ropivacaine
 - 3.4.10. Eutectic Mixture of Local Anesthetics (EMLA)
4. Intravenous Induction Agents
 - 4.1. Introduction
 - 4.2. Actions and Mechanisms of General Anesthetics
 - 4.3. Specific Agents
 - 4.3.1. Barbiturates
 - 4.3.2. Propofol
 - 4.3.3. Ketamine
 - 4.3.4. Etomidate
 - 4.3.5. Benzodiazepines

Drug Discovery**311**

Robert R. Ruffolo, *Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA*
 Jr., Frank S. Walsh, *Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA*
 Giora Z. Feuerstein, *Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA*

1. Introduction
2. The Modern Drug Discovery Process
 - 2.1. Target Selection
 - 2.2. Compound/Biological Identification
 - 2.3. Compound/Biological Optimization for Efficacy
 - 2.4. Pharmacokinetic Profiling
 - 2.5. Safety Assessment
3. Clinical Development
 - 3.1. Phase I Clinical Studies - Investigational New Drug (IND) Application
 - 3.2. Phase II Clinical Studies
 - 3.3. Phase III Clinical Studies - New Drug Application (NDA)
 - 3.4. Phase IV and Life Cycle Management
4. Translational Medicine
 - 4.1. The Role of Translational Medicine in Drug Discovery
 - 4.1.1. Disease Biomarkers
 - 4.1.2. Compound-Target Interaction Biomarkers
 - 4.1.3. Pharmacodynamic Biomarker
 - 4.1.4. Surrogate Endpoints (Biomarkers)
5. The Role of Experimental Animal Models in Drug Discovery and Development
6. The Use of Imaging Technology in Drug Discovery and Development
7. Personalized Medicine and Drug Discovery and Development
8. Conclusion

Gene Therapy

331

K.K. Jain, *Jain PharmaBiotech, Basel, Switzerland*

1. Introduction
2. Relation of Gene Therapy to Other Biotechnologies
3. Gene Therapy Technologies
 - 3.1. Classification of Gene Therapy Techniques
 - 3.2. Physical Methods of Gene Transfer
 - 3.2.1. Electroporation
 - 3.2.2. Particle Bombardment
 - 3.2.3. Ultrasound-mediated Transfection
 - 3.2.4. Molecular Vibration
 - 3.2.5. Gene Transfection using Laser Irradiation
 - 3.2.6. Photochemical Transfection
 - 3.2.7. Chemical Methods of Gene Transfer
 - 3.3. Ex vivo and In vivo Gene Therapy
 - 3.3.1. Ex vivo Gene Therapy
 - 3.3.2. In vivo Gene Therapy
 - 3.4. Gene Repair and Replacement
 - 3.4.1. Gene Repair by Single-stranded Oligonucleotides
 - 3.5. Spliceosome-mediated RNA Trans-splicing
 - 3.6. Vectors for Gene Therapy
 - 3.6.1. Use of Genes as Pharmaceuticals
 - 3.6.2. The Ideal Vector for Gene Therapy
 - 3.6.3. Viral Vectors
 - 3.6.4. Non-viral Vectors for Gene Therapy
 - 3.7. Concluding Remarks about Vectors
 - 3.8. Cell-mediated Gene Therapy
 - 3.8.1. Stem Cell Gene Therapy
 - 3.9. Routes of Administration for Gene Therapy
 - 3.10. Targeted Gene Therapy
 - 3.10.1. Controlled Induction of Gene Expression
 - 3.10.2. Controlled Gene Therapy

- 3.10.3. Technologies for Gene Suppression
- 3.10.4. Locked Nucleic Acid
- 3.11. Clinical Applications
 - 3.11.1. Strategies for Cancer Gene Therapy
 - 3.11.2. Gene Therapy of Neurological Disorders
 - 3.11.3. Gene Therapy of Cardiovascular Disorders
- 4. Concluding Remarks

Index **359**

About EOLSS **363**